Rethinking MZL: From Established Options to T-Cell–Directed Therapies

This podcast explores the evolving treatment landscape for marginal zone lymphoma (MZL), focusing on individualized treatment selection, emerging cellular therapies, and novel T-cell–engaging approaches for relapsed/refractory disease. Examine evidence supporting current treatment options, including BTK inhibitors and CAR T-cell therapy, as well as emerging clinical data on CD20 x CD3 bispecific antibodies such as odronextamab and mosunetuzumab. The discussion also addresses clinical trial referral, patient eligibility, and practical strategies for monitoring and managing treatment-related toxicities.

Presenters:
Dai Chihara, MD, PhD
Associate Professor
Department of Lymphoma and Myeloma
University of Texas MD Anderson Cancer Center
Houston, Texas

J.C. Villasboas B., MD
Assistant Professor of Medicine and Oncology
Mayo Clinic College of Medicine
Consultant, Division of Hematology, Lymphoma/Bone Marrow Transplant/Cellular Therapy Groups
Director, Mayo Clinic Immune Monitoring Core Laboratory
Rochester, Minnesota

Link to the full program:
https://bit.ly/4zw8VOq

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.